General description
Testicular germ cell tumour Ovarian germ cell tumour Osteosarcoma Rhabdomyosarcoma Ewing sarcoma.
INN
Mesna
ATC codes
Medicine type
Chemical agent
EML status history
First added in 2009
(TRS
958)
for
Unspecified malignant neoplasms of ill-defined or unspecified sites
Added in 2015
(TRS
994)
for
Osteosarcoma of bone and articular cartilage of other specified sites
Added in 2015
(TRS
994)
for
Rhabdomyosarcoma primary site
Added in 2015
(TRS
994)
for
Other specified malignant neoplasms of the ovary
Added in 2015
(TRS
994)
for
Germ cell tumour of testis
Added in 2015
(TRS
994)
for
Ewing sarcoma of bone and articular cartilage of unspecified sites
Removed in 2015
(TRS
994)
for
Unspecified malignant neoplasms of ill-defined or unspecified sites
Added in 2021
(TRS
1035)
for
Burkitt lymphoma including Burkitt leukaemia
Added in 2021
(TRS
1035)
for
Malignant neoplasms of kidney, except renal pelvis
Wikipedia
DrugBank
Recommendations
Section
Supportive medicines
- Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule
- Oral > Solid: 400 mg; 600 mg
Indications
Osteosarcoma of bone and articular cartilage of other specified sites
Rhabdomyosarcoma primary site
Other specified malignant neoplasms of the ovary
Germ cell tumour of testis
Ewing sarcoma of bone and articular cartilage of unspecified sites
Unspecified malignant neoplasms of ill-defined or unspecified sites
Burkitt lymphoma including Burkitt leukaemia
Malignant neoplasms of kidney, except renal pelvis